As a consequence, inhibition of glutaminolysis in vivo (using the GLS inhibitor CB-839, currently under clinical investigation in the treatment of hematologic malignancies and solid cancers including lung cancers) does not affect tumor cell progression (11). Here, GLS is linked to neoplasm.